Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma

8 Nov 2022

Abstract excerpt

The mitochondrion is a gatekeeper of apoptotic processes, and mediates drug resistance to several chemotherapy agents used to treat cancer. Neuroblastoma is a common solid cancer in young children with poor clinical outcomes following conventional chemotherapy. We sought druggable mitochondrial protein targets in neuroblastoma cells. Among mitochondria-associated gene targets, we found that high expression of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Histone Deacetylase Inhibitors Research
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36346110
DOI: 10.1002/ijc.34349

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastomaPMID 36346110Read ↗

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaSemantic proximity Read ↗

Therapy resistance in neuroblastoma: Mechanisms and reversal strategiesSemantic proximity Read ↗

The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma CellsSemantic proximity Read ↗

Multiple components of the spliceosome regulate Mcl1 activity in neuroblastomaSemantic proximity Read ↗

Neuroblastoma and its Target Therapies: A Medicinal Chemistry ReviewSemantic proximity Read ↗

PRMT1 promotes neuroblastoma cell survival through ATF5Semantic proximity Read ↗

Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.Semantic proximity Read ↗

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastomaSemantic proximity Read ↗

RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Semantic proximity Read ↗

Subcellular Distribution of p53 by the p53-Responsive lncRNA NBAT1 Determines Chemotherapeutic Response in NeuroblastomaSemantic proximity Read ↗

Innovative therapies for neuroblastoma: The surprisingly potent role of iron chelation in up-regulating metastasis and tumor suppressors and down-regulating the key oncogene, N-mycSemantic proximity Read ↗

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.